Erratum to: Treatment satisfaction and health status in patients with systemic sclerosis (JDDG: Journal der Deutschen Dermatologischen Gesellschaft, (2012), 10, 12, (905-911), 10.1111/j.1610-0387.2012.07995.x);Treatment satisfaction and health status in patients with systemic sclerosis;Behandlungszufriedenheit und Versorgungsstatus bei Patienten mit systemischer Sklerodermie

JDDG - Journal of the German Society of Dermatology

Volumn 10, Issue 12, 2012, Pages 905-911

  Rehberger, Philipp ^a   Müller, Hannah ^a   Günther, Claudia ^a   Schmitt, Jochen ^a  

^a UNIVERSITY OF DRESDEN MEDICAL SCHOOL   (Germany)

Author keywords

connective tissue disease; depression; disease severity; health services research; pain; sense of coherence

Indexed keywords

ANTIDEPRESSANT AGENT;

AGE; ARTICLE; CLINICAL STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE SEVERITY; EMPATHY; HEALTH STATUS; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; PAIN; PAIN ASSESSMENT; PATIENT SATISFACTION; PHYSICIAN; PROFESSIONAL COMPETENCE; QUALITY OF LIFE; QUESTIONNAIRE; SENSE OF COHERENCE; SEX; SYMPTOM; SYSTEMIC SCLEROSIS;

EID: 84870659131     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/ddg.14996     Document Type: Erratum

References (29)

1. Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J,. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 2008; 37 (4): 223-35.
2. Silman AJ,. Epidemiology of scleroderma. Ann Rheum Diss 1991; 50: 846-53.
3. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger A, Rowell N, Wollheim E,. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
4. Klein-Weigel P, Opitz C, Riemekasten G,. Systemic sclerosis-a systematic overview: part 1-disease characteristics and classification, pathophysiologic concepts, and recommendations for diagnosis and surveillance. Vasa 2011; 40 (1): 6-19.
5. Hunzelmann N, Genth E, Krieg T, Meurer M, Melchers I, Moinzadeh P, Pfeiffer C, Riemekasten G, Schulze-Lohoff E, Sunderkoetter C, Müller-Ladner U,; German Network for Systemic Sclerosis. Organ-specific diagnosis in patients with systemic sclerosis: Recommendations of the German Network for Systemic Sclerosis (DNSS). Z Rheumatol 2008; 67 (4): 334-6, 337- 40.
6. Opitz C, Klein-Weigel PF, Riemekasten G,. Systemic sclerosis-a systematic overview: part 2-immunosuppression, treatment of SSc-associated vasculopathy, and treatment of pulmonary arterial hypertension. Vasa 2011; 40 (1): 20-30.
7. Becker MO, Müller-Ladner U, Riemekasten G,. Towards an implementation of guidelines for the therapy of systemic sclerosis (scleroderma): between desire and reality. Z Rheumatol 2010; 69 (4): 310-7.
8. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
9. Müller H, Rehberger P, Günther C, Schmitt J,. Determinants of disability, quality of life and depression in dermatological patients with systemic scleroderma. Br J Dermatol 2012; 166 (2): 343-53.
10. Valentini G, D'Angelo S, Della Rossa A, Bencivelli W, Bombardieri S,. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis 2003; 62 (9): 904-5.
11. Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, Weinstein A, Weisman M, Mayes M, Collier D, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22 (7): 1281-5.
12. The Euroqol Group. EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990; 16 (3): 199-208.
13. Steen VD, Medsger TA Jr,. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997; 40 (11): 1984-91.
14. Thombs, BD, Hudson M, Schieir O, Taillefer SS, Baron M, and the Canadian Scleroderma Research Group. Reliability and validity of the center for epidemiologic studies depression scal in patients with systemic sclerosis. Arthitis Rheum 2008; 59 (3): 438-43.
15. Schmitt J, Ford DE,. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 2006; 213 (2): 102-10.
16. Antonovsky A,. The structure and properties of the sense of coherence scale. Soc Sci Med 1993; 36 (6): 725-33.
17. Eriksson M, Lindström B,. Antonovsky's sense of coherence scale and its relation with quality of life: a systematic review. J Epidemiol Community Health 2007; 61 (11): 938-44.
18. Schmitt J, Csötönyi F, Bauer A, Meurer M,. Einflussfaktoren auf Therapieziele und Behandlungszufriedenheit von Patienten mit atopischem Ekzem. J Dtsch Dermatol Ges 2006; 6: 458-66.
19. Adams R, Walsh C, Veale D, Bresnihan B, FitzGerald O, Barry M,. Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis. Pharmacoeconomics 2010; 28 (6): 477-87.
20. Hudson M, Fritzler MJ, Baron M, and the Canadian Scleroderma Research Group. Systemic sclerosis. Establishing diagnostic criteria. Medicine 2010; 89: 159-65.
21. Khanna D, Ahmed M, Furst DE, Ginsburg SS, Park GS, Hornung R, Tsevat J,. Health values of patients with systemic sclerosis. Arthr Care Res 2007; 57 (1): 86-93.
22. Poole JL, Steen VD,. The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. Arthritis Care Res 1991; 4 (1): 27-31.
23. Hannöver W, Michael A, Meyer C, Rumpf HJ, Hapke U, John U,. Antonovsky's sense of coherence scale and presentation of a psychiatric diagnosis. Psychother Psychosom Med Psychol 2004; 54 (3-4): 179-86.
24. Matsuura E, Ohta A, Kanegae F, Haruda Y, Ushiyama O, Koarada S, Togashi R, Tada Y, Suzuki N, Nagasawa K,. Frequency and analysis of factors closely associated with the development of depressive symptoms in patients with scleroderma. J Rheumatol 2003; 30 (8): 1782-7.
25. Milette K, Hudson M, Baron M, Thombs BD, and Canadian Scleroderma Research Group. Comparison of the PHQ-9 and CES-D depression scales in systemic sclerosis: internal consistency reliability, convergent validity and clinical correlates. Rheumatology 2010; 49: 789-96.
26. Schieir O, Thombs BD, Hudson M, Boivin JF, Steele R, Bernatsky S, Hanley J, Baron M, and the Canadian Scleroderma Research Group. Prevalence, Severity, and clinical correlates of pain in patients with systemic sclerosis. Arthr Care Res 2010; 62 (3): 409-17.
27. Richards HL, Fortune DG, Weidmann A, Sweeney SK, Griffiths CE,. Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient. Br J Dermatol 2004; 151 (6): 1227-33.
28. Ring J, Wahn U, Gieler U,. Neurodermitisschulung: Ein neues Behandlungsprogramm zur sekundären Krankheitsprävention. Dt Ärztebl 2001; 98: A3202-9 [Heft 48].
29. Jungblut-Wischmann P,. Allgemeine Kundenerwartungen. In:, Eichhorn P, Seelos HJ, Von der Schulenburg JM,: Krankenhausmanagement. München: Urban & Fischer, 2000: 683-94.